DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Serafini P, De Santo C, Marigo I, et al. Derangement of immune
responses by myeloid suppressor cells. Cancer Immunol
Immunother, 2003, 53:64–72.
Shah NP, Kantarjian HM, Kim D, et al. Intermittent target inhibition
with dasatinib 100 mg once daily preserves efficacy and
improves tolerability in imatinib-resistant and -intolerant
chronic-phase chronic myeloid leukemia. J Clin Oncol, 2008,
26:3204–3212.
Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance
with a novel ABL kinase inhibitor. Science, 2004, 305: 399–401.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med,
2005, 353:123–132.
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and
safety of gemtuzumab ozogamicin in patients with CD33-
positive acute myeloid leukemia in first relapse. J Clin Oncol,
2001, 19:3244–3254.
Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma
protuberans family of tumors: From ring chromosomes
to tyrosine kinase inhibitor treatment. Genes Chromosomes
Cancer, 2003, 37:1–19.
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-
2/neu proto-oncogene in human breast and ovarian cancer.
Science, 1989, 244:707–712.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic
breast cancer that overexpresses HER2. N Engl J Med, 2001,
344:783–792.
Smith KA. Interleukin-2: Inception, impact, and implications.
Science, 1988, 240:1169–1176.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive
care in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival
Evaluation in Lung Cancer). Lancet, 2005, 366:1527–1537.
Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III
study of irinotecan and 5-FU/FA with or without cetuximab
in the first-line treatment of patients with metastatic colorectal
cancer (mCRC): The CRYSTAL trial. J Clin Oncol, 2007,
25:4000.
Van Cutsem E, Siena S, Humblet Y, et al. An open-label, singlearm
study assessing safety and efficacy of panitumumab in
patients with metastatic colorectal cancer refractory to standard
chemotherapy. Ann Oncol, 2008, 19:92–98.
van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance
improves clinical outcome of relapsed/resistant follicular
non-Hodgkin lymphoma in patients both with and
without rituximab during induction: Results of a prospective
randomized phase 3 intergroup trial. Blood, 2006, 108:
3295–3301.
Vermorken JB, Mesia R, Rivera F, et al. Platinum-based
chemotherapy plus cetuximab in head and neck cancer. N Engl
J Med, 2008, 359:1116–1127.
Versluys B, Bhattacharaya R, Steward C, et al. Prophylaxis with
defibrotide prevents veno-occlusive disease in stem cell transplantation
after gemtuzumab ozogamicin exposure. Blood,
2004, 103:1968.
Villamor N, Montserrat E, Colomer D. Mechanism of action and
resistance to monoclonal antibody therapy. Semin Oncol,
2003, 30:424–433.
Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety
of trastuzumab as a single agent in first-line treatment of
HER2-over-expressing metastatic breast cancer. J Clin Oncol,
2002, 20:719–726.
Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab
ozogamicin exposure significantly increases the risk of venoocclusive
disease in patients who undergo myeloablative allogeneic
stem cell transplantation. Blood, 2003, 102: 1578–1582.
Waldmann TA. The interleukin-2 receptor. J Biol Chem, 1991,
266:2681–2684.
Weisberg E, Manley PW, Breitenstein W, et al. Characterization
of AMN107, a selective inhibitor of native and mutant bcr-abl.
Cancer Cell, 2005, 7:129–141.
Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled
trial of yttrium-90-labeled ibritumomab tiuxetan
radioimmunotherapy versus rituximab immunotherapy for
patients with relapsed or refractory low-grade, follicular, or
transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol,
2002, 20:2453–2463.
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of
bevacizumab, an anti-vascular endothelial growth factor antibody,
for metastatic renal cancer. N Engl J Med, 2003, 349:
427–434.
Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin
gamma 1I: An antitumor antibiotic that cleaves double-stranded
DNA site specifically. Science, 1988, 240:1198–1201.
1753
CHAPTER 62
TARGETED THERAPIES: TYROSINE KINASE INHIBITORS, MONOCLONAL ANTIBODIES, AND CYTOKINES